Robust Q1 Sales: Social media users highlighted Mesoblast's Ryoncil posting $30.3 million in net sales during the first quarter of 2026, pushing cumulative revenue close to $100 million since launch. Strong performance in February and March offset typical January seasonality, signaling sustained commercial momentum for the therapy in pediatric graft versus host disease.
FDA IND Clearance: Discussion intensified around the FDA granting Investigational New Drug clearance, enabling a direct path to a registrational trial for Ryoncil in Duchenne muscular dystrophy. Posters emphasized the potential breakthrough for children with this debilitating condition, with the company's R&D Day adding to the pipeline optimism.
Pipeline Progress: Overall chatter reflects growing confidence in Mesoblast's expansion efforts, though some noted sector rotation risks amid broader market dynamics. Engagement focused on factual updates rather than speculative trades.
Note: This discussion summary was generated from an AI condensation of post data.
Mesoblast Insider Trading Activity
Mesoblast insiders have traded $MESO stock on the open market 30 times in the past 6 months. Of those trades, 30 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $MESO stock by insiders over the last 6 months:
- GREGORY GEORGE has made 30 purchases buying 16,216,924 shares for an estimated $37,532,070 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Mesoblast Hedge Fund Activity
We have seen 35 institutional investors add shares of Mesoblast stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BROOKLYN INVESTMENT GROUP removed 162,612 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $2,933,520
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 158,356 shares (+58.3%) to their portfolio in Q4 2025, for an estimated $2,856,742
- BLACKROCK, INC. added 135,948 shares (+25.2%) to their portfolio in Q4 2025, for an estimated $2,452,501
- CITADEL ADVISORS LLC added 131,388 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,370,239
- MORGAN STANLEY added 131,151 shares (+28.2%) to their portfolio in Q4 2025, for an estimated $2,365,964
- JANE STREET GROUP, LLC added 126,708 shares (+311.5%) to their portfolio in Q4 2025, for an estimated $2,285,812
- UBS GROUP AG removed 114,647 shares (-61.2%) from their portfolio in Q4 2025, for an estimated $2,068,231
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Mesoblast Analyst Ratings
Wall Street analysts have issued reports on $MESO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 11/25/2025
To track analyst ratings and price targets for Mesoblast, check out Quiver Quantitative's $MESO forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
